Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention

Jaqui Walker; Marco Cattaneo; Lina Badimon; Giancarlo Agnelli; Andrew T. Chan; Angel Lanas; Bianca Rocca; Peter Rothwell; Paola Patrignani; Ruth Langley; Gemma Vilahur; Francesco Cosentino

doi:10.3332/ECANCER.2019.998

Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention

Jaqui Walker, Marco Cattaneo, Lina Badimon, Giancarlo Agnelli, Andrew T. Chan, Angel Lanas, Bianca Rocca, Peter Rothwell, Paola Patrignani, Ruth Langley, Gemma Vilahur, Francesco Cosentino

Università Cattolica del Sacro Cuore

Research output: Contribution to journal › Article › peer-review

Abstract

At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.

Original language	English
Pages (from-to)	1-13
Number of pages	13
Journal	ecancermedicalscience
Volume	14
DOIs	https://doi.org/10.3332/ECANCER.2019.998
Publication status	Published - 2020

Keywords

anticoagulant
antiplatelet
antithrombotic
aspirin
benefit
cardiovascular disease (CVD)
colorectal cancer (CRC)
diabetes mellitus (DM)
gastroprotectant agents
optimizing aspirin dose
precision medicine
primary prevention
risk
secondary prevention
targeting
upper gastrointestinal (GI) bleeding

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3332/ECANCER.2019.998

Cite this

Walker, J., Cattaneo, M., Badimon, L., Agnelli, G., Chan, A. T., Lanas, A., Rocca, B., Rothwell, P., Patrignani, P., Langley, R., Vilahur, G., & Cosentino, F. (2020). Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. ecancermedicalscience, 14, 1-13. https://doi.org/10.3332/ECANCER.2019.998

@article{008c7690372646ee8128220524202bd3,

title = "Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention",

abstract = "At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.",

keywords = "anticoagulant, antiplatelet, antithrombotic, aspirin, benefit, cardiovascular disease (CVD), colorectal cancer (CRC), diabetes mellitus (DM), gastroprotectant agents, optimizing aspirin dose, precision medicine, primary prevention, risk, secondary prevention, targeting, upper gastrointestinal (GI) bleeding, anticoagulant, antiplatelet, antithrombotic, aspirin, benefit, cardiovascular disease (CVD), colorectal cancer (CRC), diabetes mellitus (DM), gastroprotectant agents, optimizing aspirin dose, precision medicine, primary prevention, risk, secondary prevention, targeting, upper gastrointestinal (GI) bleeding",

author = "Jaqui Walker and Marco Cattaneo and Lina Badimon and Giancarlo Agnelli and Chan, {Andrew T.} and Angel Lanas and Bianca Rocca and Peter Rothwell and Paola Patrignani and Ruth Langley and Gemma Vilahur and Francesco Cosentino",

year = "2020",

doi = "10.3332/ECANCER.2019.998",

language = "English",

volume = "14",

pages = "1--13",

journal = "ecancermedicalscience",

issn = "1754-6605",

publisher = "[Bristol] : Cancer Intelligence",

}

Walker, J, Cattaneo, M, Badimon, L, Agnelli, G, Chan, AT, Lanas, A, Rocca, B, Rothwell, P, Patrignani, P, Langley, R, Vilahur, G & Cosentino, F 2020, 'Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention', ecancermedicalscience, vol. 14, pp. 1-13. https://doi.org/10.3332/ECANCER.2019.998

TY - JOUR

T1 - Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention

AU - Walker, Jaqui

AU - Cattaneo, Marco

AU - Badimon, Lina

AU - Agnelli, Giancarlo

AU - Chan, Andrew T.

AU - Lanas, Angel

AU - Rocca, Bianca

AU - Rothwell, Peter

AU - Patrignani, Paola

AU - Langley, Ruth

AU - Vilahur, Gemma

AU - Cosentino, Francesco

PY - 2020

Y1 - 2020

N2 - At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.

AB - At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.

KW - anticoagulant

KW - antiplatelet

KW - antithrombotic

KW - aspirin

KW - benefit

KW - cardiovascular disease (CVD)

KW - colorectal cancer (CRC)

KW - diabetes mellitus (DM)

KW - gastroprotectant agents

KW - optimizing aspirin dose

KW - precision medicine

KW - primary prevention

KW - risk

KW - secondary prevention

KW - targeting

KW - upper gastrointestinal (GI) bleeding

KW - anticoagulant

KW - antiplatelet

KW - antithrombotic

KW - aspirin

KW - benefit

KW - cardiovascular disease (CVD)

KW - colorectal cancer (CRC)

KW - diabetes mellitus (DM)

KW - gastroprotectant agents

KW - optimizing aspirin dose

KW - precision medicine

KW - primary prevention

KW - risk

KW - secondary prevention

KW - targeting

KW - upper gastrointestinal (GI) bleeding

UR - http://hdl.handle.net/10807/147317

U2 - 10.3332/ECANCER.2019.998

DO - 10.3332/ECANCER.2019.998

M3 - Article

SN - 1754-6605

VL - 14

SP - 1

EP - 13

JO - ecancermedicalscience

JF - ecancermedicalscience

ER -

Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this